Maze Therapeutics, Inc. (MAZE): Total Liabilities
$42.16M
As of 2025-12-31
$78.50M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.16M | -3.4% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $43.64M | n/a | 2026-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $42.16M | -3.4% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $158.78M | +49.4% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $123.36M | -2.5% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $256.01M | +2.2% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $576.73M | +101.9% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $102.49M | -23.3% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $39.64M | +25.9% |
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $194.15M | +4.8% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
Compare MAZE, SRRK, ALLO, SANA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗